Microcap Ledger Perspective Therapeutics, Inc. $CATX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- NYSE American
- Sector
- Pharmaceutical Preparations
- Headquarters
- Seattle, WA
- Fiscal year end
- December 31
- Shares outstanding
- 114,151,663 [10-Q 2026-08-10]
What the company doesAI summary of filing
Perspective Therapeutics, Inc. develops targeted alpha therapy drug product candidates for cancer treatment. The company is in the clinical trial stage, with product candidates including PSV359, which it is pursuing for FDA Fast Track designation. The company operates manufacturing facilities for drug product finishing and plans to expand its regional network and distribution capabilities. The company is pre-revenue and states it believes its cash resources will be sufficient to fund planned clinical milestones and operational investments into late 2027. [10-K 2026-03-16]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$52.98M | −$52.12M | $48.49M | [10-Q 2026-08-10] |
| FY ended Dec 2025 | — | −$103.12M | −$82.48M | $30.63M | [DEF 14A 2026-04-16] |
| FY ended Dec 2024 | — | −$79.28M | −$18.29M | $61.58M | [DEF 14A 2026-04-16] |
- Quarterly cash burn
- −$26.06M
- Cash runway Estimate
- ~5.6 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-07 | 67,587,540 | [10-Q 2024-11-12] |
| 2025-03-21 | 74,051,841 | [10-K/A 2025-03-28] |
| 2025-05-07 | 74,228,334 | [10-Q 2025-05-12] |
| 2025-08-11 | 74,262,990 | [10-Q 2025-08-13] |
| 2025-11-06 | 74,337,990 | [10-Q 2025-11-10] |
| 2026-03-12 | 113,933,436 | [10-K 2026-03-16] |
| 2026-05-06 | 114,046,197 | [10-Q 2026-05-11] |
| 2026-08-05 | 114,151,663 | [10-Q 2026-08-10] |
- Shelf registration
- S-3ASR filed 2024-05-24; declared effective 2025-04-08 [S-3ASR 2024-05-24]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-04 | Lantheus Alpha Therapy, Llc | sell | 167,149 | $3.15 | [4 2026-09-08] |
| 2026-09-03 | Lantheus Alpha Therapy, Llc | sell | 80,783 | $3.11 | [4 2026-09-08] |
| 2026-09-02 | Lantheus Alpha Therapy, Llc | sell | 42,129 | $3.11 | [4 2026-09-04] |
| 2026-09-01 | Lantheus Alpha Therapy, Llc | sell | 35,769 | $3.12 | [4 2026-09-04] |
| 2026-09-01 | Lantheus Holdings, Inc. | sell | 35,769 | $3.12 | [4 2026-09-03] |
| 2026-08-31 | Lantheus Alpha Therapy, Llc | sell | 78,145 | $3.14 | [4 2026-09-04] |
| 2026-08-31 | Lantheus Holdings, Inc. | sell | 78,145 | $3.14 | [4 2026-09-02] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-08 | 8-K | Other events |
| 2026-10-01 | 8-K | Other events |
| 2026-09-23 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-09-14 | 8-K | Other events |
| 2026-09-08 | 8-K | Other events |
| 2026-09-04 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-10 | 10-Q | Quarterly report |
| 2026-08-10 | 8-K | Results of operations; Other events |
| 2026-08-07 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-03 | 8-K | Other events |
| 2026-07-29 | 13G | Beneficial ownership report (5%+ holder) |
Alerts for $CATX
Email me when Perspective Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.